Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Leap Therapeutics Q3 EPS $(0.08) Beats $(0.24) Estimate

Author: Benzinga Newsdesk | November 12, 2025 08:15am
Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.24) by 66.67 percent. This is a 81.82 percent increase over losses of $(0.44) per share from the same period last year.

Posted In: LPTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist